Leukemia
Leukemia
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
34
Clinical Trials
Leukemia
Phase III
Accepting Patients
nct/study# NA / COMPASSIONATE-USE-PACRITINIB
Individual Patient Supply Of Oral Pacritinib In A Patient With Thrombocytopenia And Primary Myelofibrosis.
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT03915379 / JNJ-67571244-AML-1001
A Phase 1, First-In-Human, Dose Escalation Study Of JNJ-67571244 (Bispecific Antibody Targeting CD33 And CD3) In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Learn More
Leukemia
Phase I
Accepting Patients
nct/study# NCT04075747 / JZP025-101
V-FAST: A Phase 1b Master Trial To Investigate CPX-351 Combined With Various Targeted Agents In Subjects With Previously Untreated Acute Myeloid Leukemia
Learn More
Leukemia
Phase III
Accepting Patients
nct/study# NCT03589326 / PONATINIB-3001
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered In Combination With Reduced-Intensity Chemotherapy, In Patients With Actively Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Learn More
Leukemia
Phase II
Active
nct/study# NA / BST004
A Phase 2, Open Label, Single Arm, Multi‐Center Study To Assess The Efficacy And Safety Of BST‐236 As A Single Agent In Adults Unfit For Intensive Chemotherapy With Relapsed Or Refractory Acute Myeloid Leukemia Or Higher-Risk Myelodysplastic Syndrome?
Learn More
Leukemia
Phase II
Active
nct/study# NA / SY-1425-202
Phase II RARA(+) Actively Diagnosed/Untreated AML Study With Venetoclax/Azacitidine And SY-1425 With The Primary Objective To Characterize The Safety And Tolerability Of The Triplet Regimen.
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.